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Thrombocytopenia-associated multiple organ failure (TAMOF) has a high mortal-
ity rate when not treated, and early detection of TAMOF is very important diag-
nostically and therapeutically. We describe herein our experience of early detection 
of TAMOF, using an automated hematology analyzer. From 498,390 inpatients, 
we selected 12 patients suspected of having peripheral schistocytosis, based on the 
results of red blood cell (RBC) parameters and a volume/hemoglobin concentra-
tion (V/HC) cytogram. We promptly evaluated whether the individual patients had 
clinical manifestations and laboratory findings were consistent with TAMOF. Plas-
ma exchanges were then performed for each patient. All 12 patients had TAMOF. 
The mean values of RBC parameters were significantly higher in all of the patients 
than with the reference range, however, 3 patients had % RBC fragments within 
the reference range. The mean value of ADAMTS-13 activity was slightly lower 
in patients compared with the reference range. Of the 12 patients, remission was 
obtained in 9 patients (75%) within 4 to 5 weeks using plasma exchanges. Three 
patients died. An increased percentage of microcytic hyperchromic cells with aniso-
cytosis and anisochromia indicated the presence of schistocytes, making it an excel-
lent screening marker for TAMOF. Identification of TAMOF with RBC parameters 
and a V/HC cytogram is a facile and rapid method along with an automated hema-
tology analyzer already in use for routine complete blood cell counting test.
Key Words:    Thrombocytopenia-associated multiple organ failure, hematology ana-
lyzer, RBC parameter, volume/hemoglobin concentration cytogram
Thrombocytopenia-associated multiple organ failure (TAMOF) is a recently ap-
preciated syndrome in critically ill patients.1 Thrombotic thrombocytopenic purpu-
ra (TTP), hemolytic uremic syndrome (HUS), consumptive disseminated intravas-Jong-Ha Yoo, et al.
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herein our experience of early detection of TAMOF using 
an automated hematology analyzer. 
We reviewed RBC parameters and V/HC cytograms of 
498,390 inpatients between January 2007 and December 
2008, and selected 12 patients who were suspected of having 
peripheral schistocytosis. We used the following criteria in 
screening for schistocytosis according to the manufacturer’s 
instructions (ADVIA 120; Siemens, Forchheim, Germany): 
RDW >14.5%, HDW >3.2 g/dL, % microcytes (% micro) 
≥0.4%, and % hyperchromic red cells (% hyper) ≥1.9%. A 
typical V/HC cytogram showing increased numbers of micro-
cytic hyperchromic RBCs10 is shown in Fig. 1. We promptly 
reviewed patients’ medical records to determine whether 
they had clinical manifestations and laboratory findings con-
sistent with TAMOF. Plasma exchanges were then per-
formed for each patient. Cryo-preserved supernatant (fresh 
frozen plasma minus cryoprecipitate) was used as replace-
ment fluid for plasma exchange, because this product is poor 
in large von Willebrand factor (vWF) multimers.1 The end-
point for the plasma exchange was the resolution of the 
thrombocytopenia (platelet count >140×103/μL). This study 
was approved by the hospital ethics committee.
A complete blood cell counting was performed within 2 
hours of blood drawing with an automated hematology an-
alyzer (ADVIA 120), using ethylenediaminetetraacetic acid 
(EDTA)-anticoagulated blood, and RBC parameters such 
as RDW, HDW, % micro, % hyper, and % RBC fragments 
were evaluated. The V/HC cytogram is a linear version of 
the RBC map that appears on the RBC cytogram. On a V/
HC cytogram, the hemoglobin concentration is plotted along 
cular coagulation (DIC), and non-consumptive secondary 
thrombotic microangiopathy (TMA) are included in 
TAMOF. Critically ill patients develop systemic endothelial 
injury due to exposure to transplantation, cardiopulmonary 
bypass, autoimmune disease, infection, cancer, radiation, 
and medications. 
It has long been established that patients with TAMOF 
have an unfavorable prognosis in the absence of treatment.2,3 
Many clinical studies have suggested that an early use of 
plasma exchange therapy for TTP, HUS, non-consumptive 
secondary TMA, and even for consumptive DIC improve 
survival.4-8 Therefore, early detection of TAMOF is critical-
ly important diagnostically and therapeutically.
Schistocytes in blood indicate the possibility of TAMOF,2 
but an optical counting of schistocytes is both time-con-
suming and variable among individual examiners. Auto-
mated hematology analyzers are used for the direct mea-
surement of red blood cell (RBC) fragments,3,9 however, 
the specificity is very broad (20-96%). Furthermore, in non-
consumptive secondary TMA, there is little evidence of he-
molysis in peripheral blood, and the percentage of schisto-
cytes is lower than that of the primary form.1 Therefore, it is 
difficult to confirm the presence of schistocytes on a blood 
smear examination in secondary TMA patients.
Schistocytes can show microcytic hyperchromia, an in-
creased red cell distribution width (RDW), and an increased 
hemoglobin distribution width (HDW).10 Based on these 
characteristics of schistocytes, we used RBC parameters and 
a volume/hemoglobin concentration (V/HC) cytogram as a 
screening test for the detection of TAMOF. We describe 
Fig. 1. A red blood cell (RBC) volume/hemoglobin concentration (V/HC) cytogram. (A) Normal RBC V/HC cytogram. Hemoglobin concen-
tration is plotted along the x-axis, and the mean corpuscular volume (MCV) of the RBCs is plotted along the y-axis. (B) The RBC V/HC cy-
togram of a representative patient with TAMOF (case 6). Percent micro indicates the percent of RBCs smaller than 60 fL and % hyper indi-
cates the percent of RBCs with more than 41 g/dL of hemoglobin. HGB, hemoglobin.
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A total of 12 patients were all compatible with the diagno-
sis of TAMOF. The standardized annual hospital incidence 
was 2.4/100,000. The incidence was constant during the 2 
years of the study (2007: 2.5/100,000; 2008: 2.3/100,000). 
The patients’ characteristics, including their underlying 
disorders, are presented in Table 1. Sepsis and/or cancer 
were the most common conditions associated with TAMOF. 
Among the 12 patients, 5 were diagnosed with DIC (ISTH 
DIC score ≥5 points) and 7 were diagnosed with secondary 
TMA according to the following diagnostic criteria: throm-
bocytopenia, increased LDH, ≥1% schistocytes on a stained 
peripheral blood smear, and multiple organ failure. The mean 
values of the RBC parameters (% micro, % hyper, RDW, 
and HDW) were significantly higher in all of the patients 
with TAMOF compared with the reference range, but the 
% RBC fragments measurement was within the reference 
range in 3 patients. The mean value of ADAMTS-13 activi-
ty (54.2%) was slightly lower in the patients with TAMOF 
compared to the reference range (70-160%), but there were 
no cases of severe ADAMTS-13 deficiency (<5%).
Remission was obtained in 9 patients (75%) within 4 to 5 
weeks using plasma exchanges. Three patients died. Of the 
9 survivors, a 6-month follow-up was available for 2 patients 
(cases 7 and 8). They showed continuous remission (plate-
let count: 199 and 235×103/μL, respectively). A mean num-
ber of 3.5 plasma exchanges were performed for each pa-
tient. The number of plasma exchanges in non-survivors 
was less than that of the survivors (1.3 and 4.2, respective-
ly). The mean SOFA score was 11.
An increased percentage of microcytic hyperchromic cells 
with anisocytosis and anisochromia indicated the presence of 
schistocytes, making it an excellent automated screening 
marker of TAMOF. Initially, all patients lacked clinical evi-
dence of TAMOF except thrombocytopenia. Using RBC pa-
rameters (% micro, % hyper, RDW, and HDW) and a V/HC 
cytogram, we successfully selected patients with TAMOF. 
No false-positive cases were found. 
On the ADVIA 120, the % RBC fragments measurement 
corresponds to events of volume smaller than 30 fL with a 
refractive index greater than 1.4. Lesesve, et al.3 evaluated 
the sensitivity and specificity of the automated measure-
ment of % RBC fragments in patients with TTP, HUS, or 
microangiopathy, and found that the % RBC fragments mea-
surement has a high negative predictive value, but the spec-
ificity is low (20%). In the present study, the sensitivity of 
the % RBC fragments measurement was 100% in patients 
with DIC, but was only 57% in patients with secondary TMA 
the x-axis and cell volume is plotted along the y-axis (Fig. 1). 
The % micro and % hyper were calculated from the V/HC 
cytogram. The % micro indicates the percent of RBCs 
smaller than 60 fL, and the % hyper indicates the percent of 
RBCs with more than 41 g/dL of hemoglobin. For compari-
son, the schistocyte percent was estimated by microscopical-
ly counting 1,000 red cells on blood films, after Wright-Gi-
emsa staining.
Other laboratory tests used for the diagnosis of TAMOF 
included prothrombin time (PT), activated partial thrombo-
plastin time (aPTT), fibrinogen, D-dimer, lactate dehydro-
genase (LDH), and ADAMTS-13. PT, aPTT, and fibrino-
gen were measured using an STA compact (Diagnostica 
Stago, Asnieres-sur-Seine, France). D-dimer measurements 
were performed using VIDAS (BioMerieux, Marcy L’Etoile, 
France). LDH was measured using an Olympus AU2700 
(Olympus, Tokyo, Japan). ADAMTS-13 activity was mea-
sured using a Technozym ADAMTS-13 activity ELISA kit 
(Technoclone, Heidelberg, Germany).
Sequential Organ Failure Assessment (SOFA) score is a 
scoring system used to determine the extent of organ func-
tion and has been shown to be related to mortality. Here, 
SOFA scores were determined 24 hr after admission ac-
cording to the known SOFA score system.11,12 The SOFA 
score for the central nervous system in sedated patients was 
calculated using the Glasgow coma score which is based on 
the assessment of the patient before sedation.
DIC scores were calculated according to the recommen-
dations of the ISTH.13 The International Society on Throm-
bosis and Haemostasis (ISTH) scoring system is based on 
the presence of an underlying DIC-prone disease and well-
defined routine coagulation parameters that are easy to as-
say. Coagulation parameters used to calculate the overt DIC 
score included the platelet count, PT, fibrinogen, and D-di-
mer. The score points were assigned as follows: platelet 
count ≥100×103/μL=0 point, <100 but ≥50×103/μL=1 
point, <50×103/μL=2 points; prolongation of PT ≤3 s=0 
point, >3 but ≤6 s=1 point, >6 s=2 points; and fibrinogen 
level >100 mg/dL=0 point, ≤100 mg/dL=1 point. Recently 
proposed cut-off values for D-dimer assay were used.14 Ac-
cording to the values of D-dimer, either below 25% quartile, 
between 25% and 75% quartiles, or above 75% quartile, 0 
point was given for not increased, 2 points for increased, and 
3 points for strongly increased. D-dimer values were <0.5 
μg/mL=0 point, ≥0.5 and <3.6 μg/mL=2 points, ≥3.6 μg/
mL=3 points. A score of at least 5 points was defined as overt 
DIC according to the recommendations of the ISTH.13Jong-Ha Yoo, et al.
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rate in the absence of treatment, it is important to diagnose 
it and use plasma exchange therapy in early stages of the 
disease or during an acute TMA episode.17,20 We think that 
the detection of peripheral schistocytosis using RBC pa-
rameters is a rapid and cost-effective laboratory test, and is 
suitable as the first step analysis in defining TAMOF.  
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